WASHINGTON  — As 200 health care data wonks packed into a room just a block from the White House to consider the question of how to use “real world” data to do clinical research, they struggled with the fact that the health care system has been generating reams of data unfit for that specific purpose.

“What we have is an [electronic health record] system that is not primarily built for research, and yet we need to see if we can use it for research,” Rich Moscicki, the Food and Drug Administration’s deputy center director for science operations at the Center for Drug Evaluation and Research, told STAT. In October Moscicki will join Pharmaceutical Research and Manufacturers of America as the trade group’s chief medical officer and executive vice president.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy